Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis

Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation. In the phase 3 study (NCT02414854), add-on dupilumab 200 mg/300 mg every 2 weeks, versus placebo, significantly reduced severe asthma exacerbations and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2020-02, Vol.8 (2), p.527-539.e9
Hauptverfasser:	Maspero, Jorge F., Katelaris, Constance H., Busse, William W., Castro, Mario, Corren, Jonathan, Chipps, Bradley E., Peters, Anju T., Pavord, Ian D., Ford, Linda B., Sher, Lawrence, Rabe, Klaus F., Rice, Megan S., Rowe, Paul, Lu, Yufang, Harel, Sivan, Jagerschmidt, Alexandre, Khan, Asif H., Kamat, Siddhesh, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Graham, Neil M.H., Mannent, Leda P., Teper, Ariel
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Asthmatic Agents - therapeutic use Anti-IL-13 Anti-IL-4 Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - complications Asthma - drug therapy Biomarkers Bronchodilators Chronic rhinosinusitis Comorbidity Double-Blind Method Dupilumab Efficacy Humans Immunotherapy Inflammation Injections, Subcutaneous Interleukin 13 Interleukin 4 Monoclonal antibodies Patient safety Phenotypes Population Quality of Life Questionnaires Respiratory function Rhinitis Rhinitis - complications Rhinosinusitis Safety Self Report Sinusitis Sinusitis - complications Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!